SKY92联合R-ISS对老年多发性骨髓瘤的预后与预测价值:HOVON-87/NMSG-18试验
该研究在HOVON-87/NMSG-18试验的168例老年多发性骨髓瘤患者中,将SKY92分类器与R-ISS联合构建SKY-RISS模型。SKY-RISS将患者分为三组,3年总生存率分别为88%、66%、26%(P=6×10-7),并在CoMMpass数据集验证。SKY-RISS高危患者中,MPR-R较MPT-T显示生存获益(中位OS 55 vs 14个月)。
要点
- SKY-RISS模型在老年MM中区分三组,3年OS率分别为88%、66%、26%。
- SKY92高危患者3年OS率28%,显著低于标危的70%。
- SKY-RISS高危患者中,MPR-R较MPT-T显示生存获益(中位OS 55 vs 14个月)。
核心结论
- SKY92联合R-ISS可更准确地对老年多发性骨髓瘤患者进行风险分层。
- SKY-RISS高危患者可能从MPR-R方案中获得优于MPT-T的生存获益。
研究设计与样本
- 研究基于HOVON-87/NMSG-18试验(EudraCT: 2007-004007-34),纳入168例有R-ISS状态和基因表达谱的老年多发性骨髓瘤患者。
- 试验比较MPT-T方案与MPR-R方案。
- SKY-RISS模型在CoMMpass数据集的老年患者中进行验证。
主要发现
- R-ISS I、II、III期分别占8%、75%、7%,3年OS率分别为80%、65%、33%(P=8×10-3)。
- SKY92高危患者占13%,3年OS率28%,标危为70%(P<.001)。
- SKY-RISS I、II、III组分别占15%、74%、11%,3年OS率分别为88%、66%、26%(P=6×10-7)。
- 在SKY-RISS高危患者中,MPR-R与MPT-T的中位OS分别为55个月和14个月。
关键数值与推荐
- R-ISS分期:I期3年OS率80%,II期65%,III期33%(P=8×10-3)。
- SKY92高危:3年OS率28%,标危70%(P<.001)。
- SKY-RISS I期3年OS率88%,II期66%,III期26%(P=6×10-7)。
- SKY-RISS高危患者中,MPR-R中位OS 55个月,MPT-T 14个月。
临床怎么用
- 在老年多发性骨髓瘤患者中,可考虑采用SKY-RISS模型进行更精确的预后分层。
- 对于SKY-RISS高危患者,MPR-R方案可能优于MPT-T,但需进一步验证。
局限性
- 研究样本量有限(168例),且为回顾性分析。
- SKY-RISS的预测性获益仅在SKY92-RISS高危患者中观察到,需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk ratio is reduced because of comorbidities and subsequent side effects. We hypothesized that adding gene-expression data to R-ISS would generate a stronger marker. This was tested by combining R-ISS with the SKY92 classifier (SKY-RISS). The HOVON-87/NMSG-18 trial (EudraCT: 2007-004007-34) compared melphalan-prednisone-thalidomide followed by thalidomide maintenance (MPT-T) with melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R). From this trial, 168 patients with available R-ISS status and gene-expression profiles were analyzed. R-ISS stages I, II, and III were assigned to 8%, 75%, and 7% of patients, respectively (3-year overall survival [OS] rates: 80%, 65%, 33%, P = 8 × 10-3). Using the SKY92 classifier, 13% of patients were high risk (HR) (3-year OS rates: standard risk [SR], 70%; HR, 28%; P < .001). Combining SKY92 with R-ISS resulted in 3 risk groups: SKY-RISS I (SKY-SR + R-ISS-I; 15%), SKY-RISS III (SKY-HR + R-ISS-II/III; 11%), and SKY-RISS II (all other patients; 74%). The 3-year OS rates for SKY-RISS I, II, and III are 88%, 66%, and 26%, respectively (P = 6 × 10-7). The SKY-RISS model was validated in older patients from the CoMMpass dataset. Moreover, SKY-RISS demonstrated predictive potential: HR patients appeared to benefit from MPR-R over MPT-T (median OS, 55 and 14 months, respectively). Combined, SKY92 and R-ISS classify patients more accurately. Additionally, benefit was observed for MPR-R over MPT-T in SKY92-RISS HR patients only.
引用
- Kuiper R, Zweegman S, van Duin M, et al. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Adv. 2020. PMID: 33351127. doi:10.1182/bloodadvances.2020002838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。